Telitacicept Clinical Trials (2026): 46 Studies for Systemic Lupus Erythematosus & Telitacicept
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
46 Telitacicept clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 33 indications (including Systemic Lupus Erythematosus & Telitacicept) and 4,408 total planned enrollment. 13 Phase 3 Telitacicept trials and 11 Phase 2, 9 Phase 4 are listed. 26 Telitacicept clinical trials are actively recruiting at 46 U.S. sites across 18 states. Most recent activity: NCT07495033 (May 2030).
Where to Participate: All Telitacicept Trial Sites in the U.S. (46 sites across 18 states)
Every actively recruiting Telitacicepttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Arizona Arthritis & Rheumatology Associates P.C. | Chandler85225 | NCT07404865 | Map |
| AZ | Arizona Arthritis & Rheumatology Associates P.C. | Flagstaff86001 | NCT07404865 | Map |
| AZ | Arizona Arthritis & Rheumatology Associates, PLLC | Glendale85306 | NCT07404865 | Map |
| AZ | Arizona Arthritis & Rheumatology Associates P.C. | Phoenix85392 | NCT07404865 | Map |
| AZ | Arizona Arthritis & Rheumatology Associates, P.C. | Tucson85704 | NCT07404865 | Map |
| CA | Wallace Rheumatic Study Center | Beverly Hills90210 | NCT07404865 | Map |
| CA | University of Southern California | Los Angeles90033 | NCT06456580 | Map |
| CA | University of California Irvine | Orange92868 | NCT06456580 | Map |
| CA | University of California San Francisco (UCSF) | San Francisco94143 | NCT06456580 | Map |
| CO | Denver Arthritis Clinic | Denver80230 | NCT07404865 | Map |
| FL | SFM Clinical Research | Boca Raton33487 | NCT06456580 | Map |
| FL | Finlay Medical Research Corp | Green Acres33467 | NCT07404865 | Map |
| FL | Allied Biomedical Research Institute (ABRI) | Miami33155 | NCT06456580 | Map |
| FL | Suncoast Clinical Research Inc. | New Port Richey34652 | NCT07404865 | Map |
| FL | Medsol Clinical Research Center | Port Charlotte33952 | NCT06456580 | Map |
| FL | University of South Florida Health (USF Health) | Tampa33613 | NCT06456580 | Map |
| GA | Wellstar MCG Health Medical Center | Augusta30912 | NCT06456580 | Map |
| IL | Chicago Clinical Research Institute Inc | Chicago60607 | NCT07404865 | Map |
| IL | Clinical Investigation Specialist | Schaumburg60195 | NCT07404865 | Map |
| IL | Willow Rheumatology & Wellness | Willowbrook60527 | NCT07404865 | Map |
| KS | University of Kansas Medical Center | Kansas City66160 | NCT06456580 | Map |
| KY | University of Kentucky | Lexington40506 | NCT06456580 | Map |
| KY | University of Louisville Physicians | Louisville40202 | NCT06456580 | Map |
| LA | Accurate Clinical Research, Inc. | Lake Charles70605 | NCT07404865 | Map |
| MD | Arthritis and Rheumatism Associates | Rockville20850 | NCT07404865 | Map |
| MA | Neurology Center of New England | Foxborough02035 | NCT06456580 | Map |
| MI | Michigan State University Clinical Center | East Lansing48824 | NCT06456580 | Map |
| MI | Trinity Health - Grand Rapids Hospital | Grand Rapids49503 | NCT06456580 | Map |
| NY | Mount Sinai Health System | New York10029 | NCT06456580 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT06456580 | Map |
| OH | University of Cincinnati Health Physicians - Clifton | Cincinnati45219 | NCT06456580 | Map |
| PA | Altoona Center for Clinical Research, P.C. | Duncansville16635 | NCT07404865 | Map |
| PA | Rheumatic Disease Associates, Ltd. | Willow Grove19090 | NCT07404865 | Map |
| TX | Allen Arthritis | Allen75013 | NCT07404865 | Map |
| TX | Arthritis and Rheumatology Research Institute, PLLC | Allen75013 | NCT07404865 | Map |
| TX | Accurate Clinical Research | Baytown77521 | NCT07404865 | Map |
| TX | Novel Research LLC | Bellaire77401 | NCT07404865 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06456580 | Map |
| TX | Precision Comprehensive Clinical Research Solutions | Euless76040 | NCT07404865 | Map |
| TX | Lone Star Arthritis & Rheumatology | Fort Worth76109 | NCT07404865 | Map |
| TX | Accurate Clinical Research, Inc. | Houston77089 | NCT07404865 | Map |
| TX | Houston Methodist Neurological Institute | Houston77030 | NCT06456580 | Map |
| TX | R&H Clinical Research Inc. | Katy77450 | NCT07404865 | Map |
| TX | Velocity Clinical Research, Waco | Waco76710 | NCT07404865 | Map |
| VA | Tidewater Clinical Research | Chesapeake23320 | NCT07404865 | Map |
| WI | Center for Neurological Disorders, S.C. - Greenfield - Gamma Therapeutic Center | Greenfield53228 | NCT06456580 | Map |
Telitacicept clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|
| P1 | 1 | 2 | 3 | |||||
| P1/P2 | 1 | 1 | ||||||
| P2 | 5 | 1 | 1 | 2 | 1 | 1 | 11 | |
| P2/P3 | 2 | 2 | ||||||
| P3 | 4 | 2 | 2 | 1 | 1 | 2 | 1 | 13 |
| P4 | 4 | 1 | 2 | 2 | 9 | |||
| N/A | 3 | 2 | 2 | 7 |
Recruiting Telitacicept clinical trials (26)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07495033 | Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease | P3 | CTD-ILD | 260 | Apr 2026 |
| NCT07340463 | The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | P2 | Systemic Lupus Erythematosus (SLE) | 50 | Dec 2025 |
| NCT07404865 | UPSTREAM SjDPhase 3 Study of Telitacicept in Active Primary Sjögren's Disease | P3 | Primary Sjogren's Disease | 250 | Feb 2026 |
| NCT06456580 | UPSTREAM MGA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | P3 | Generalized Myasthenia Gravis | 180 | Jul 2024 |
| NCT07522099 | Chinese Adults With Kidney Disease | P2 | Immunoglobulin A Nephropathy (IgAN) | 30 | May 2026 |
| NCT07298928 | A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis | N/A | Effectiveness | 30 | Mar 2026 |
| NCT06375005 | Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis | P2 | Diffuse Cutaneous Systemic Sclerosis | 38 | Jan 2025 |
| NCT06125405 | STERNStudy of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome | P3 | Nephrotic Syndrome in Children | 20 | Nov 2023 |
| NCT06614985 | TEST-T-PMNThe Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy | P2 | Primary Membranous Nephropathy | 172 | Oct 2024 |
| NCT07052981 | Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis | P3 | IgA Nephropathy (IgAN) | 124 | Aug 2025 |
| NCT06394063 | Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients | N/A | Systemic Lupus Erythematosus | 176 | Jun 2024 |
| NCT06979271 | Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis | — | Telitacicept | 20 | Jun 2025 |
| NCT07355257 | TELITACICEPT-IMTELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) | P2/P3 | Inflammatory Myopathy | 30 | Feb 2026 |
| NCT07077486 | Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease | P4 | Lupus or SLE | 100 | Aug 2025 |
| NCT07249632 | OMGA Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | P3 | Myasthenia Gravis, Ocular | 120 | Jan 2026 |
| NCT06827587 | Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis | N/A | Myasthenia Gravis | 60 | Feb 2025 |
| NCT06723548 | Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis | P4 | Myasthenia Gravis | 30 | Dec 2024 |
| NCT06654596 | Efficacy and Safety of Telitacicept in IgAN | N/A | IgA Nephropathy (IgAN) | 118 | Dec 2024 |
| NCT05962840 | TTCAAVREMEfficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) | P4 | ANCA Associated Vasculitis | 40 | Jun 2023 |
| NCT05965284 | TTCAZAREMEfficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) | P4 | ANCA-associated Vasculitis | 40 | Mar 2023 |
| NCT05596708 | Study of Telitacicept in Patients With Refractory IgA Nephropathy | P2/P3 | IgA Nephropathy | 40 | Mar 2023 |
| NCT06546540 | The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis | P4 | Systemic Sclerosis | 20 | Jun 2024 |
| NCT07008196 | Telitacicept for the Treatment of Refractory RA | P4 | Rheumatoid Arthritis (RA) | 30 | Jun 2025 |
| NCT05680480 | A Study of Telitacicept in Lupus Nephritis | P2 | Lupus Nephritis | 120 | Apr 2023 |
| NCT05998759 | Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia | P2 | Connective Tissue Diseases | 296 | Dec 2023 |
| NCT06549959 | PKA Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects | P1 | Healthy | 248 | Aug 2024 |
Telitacicept clinical trials by indication
Systemic Lupus Erythematosus (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06394063 | — | N/A | recruiting | Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients |
| NCT05687526 | — | P1 | completed | A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus |
| NCT05339217 | — | P3 | unknown | Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus |
| NCT06456567 | REMESLE-2 | P3 | withdrawn | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) |
| NCT05306574 | REMESLE-1 | P3 | terminated | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) |
| NCT05929248 | — | P2 | unknown | Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia |
| NCT05666336 | — | P4 | unknown | Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients |
| NCT05247203 | — | P1 | completed | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
IgA Nephropathy (IgAN) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07052981 | — | P3 | not yet recruiting | Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis |
| NCT06654596 | — | N/A | recruiting | Efficacy and Safety of Telitacicept in IgAN |
| NCT07098897 | — | P3 | active not recruiting | To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy |
Systemic Lupus Erythematosus (SLE) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07340463 | — | P2 | recruiting | The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment |
| NCT06677801 | — | P4 | active not recruiting | Immune Cell Subsets in SLE Patients Treated with Telitacicept |
Myasthenia Gravis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06827587 | — | N/A | not yet recruiting | Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis |
| NCT06723548 | — | P4 | not yet recruiting | Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis |
Lupus Nephritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05680480 | — | P2 | recruiting | A Study of Telitacicept in Lupus Nephritis |
| NCT05588830 | — | N/A | unknown | The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study |
IgA Nephropathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05596708 | — | P2/P3 | not yet recruiting | Study of Telitacicept in Patients With Refractory IgA Nephropathy |
| NCT04905212 | RC18 | P2 | terminated | A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy |
Immunoglobulin A Nephropathy (IgAN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07522099 | — | P2 | recruiting | Chinese Adults With Kidney Disease |
CTD-ILD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07495033 | — | P3 | not yet recruiting | Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease |
Effectiveness (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07298928 | — | N/A | not yet recruiting | A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis |
Primary Sjogren's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07404865 | UPSTREAM SjD | P3 | recruiting | Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease |
Inflammatory Myopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07355257 | TELITACICEPT-IM | P2/P3 | not yet recruiting | TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) |
Myasthenia Gravis, Ocular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07249632 | OMG | P3 | recruiting | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) |
Lupus or SLE (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07077486 | — | P4 | recruiting | Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease |
Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07111338 | — | P2 | active not recruiting | Telitacicept for PGNMID: A Single-Arm Study |
Rheumatoid Arthritis (RA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07008196 | — | P4 | not yet recruiting | Telitacicept for the Treatment of Refractory RA |
Telitacicept (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06979271 | — | N/A | recruiting | Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis |
Diffuse Cutaneous Systemic Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06375005 | — | P2 | recruiting | Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis |
Primary Membranous Nephropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06614985 | TEST-T-PMN | P2 | not yet recruiting | The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy |
Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06656962 | TEST-T-AAGN | P1/P2 | active not recruiting | The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06549959 | PK | P1 | recruiting | A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects |
Generalized Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06456580 | UPSTREAM MG | P3 | recruiting | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) |
Systemic Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06546540 | — | P4 | recruiting | The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis |
Connective Tissue Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05998759 | — | P2 | recruiting | Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
Antiphospholipid Syndrome (APS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06315530 | — | P2 | completed | Effect of Telitacicept on Antibody Titers in Primary APS Patients |
Nephrotic Syndrome in Children (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06125405 | STERN | P3 | recruiting | Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome |
ANCA Associated Vasculitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05962840 | TTCAAVREM | P4 | recruiting | Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) |
Primary IgA Nephropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05799287 | TELIGAN | P3 | active not recruiting | A Study of Telitacicept for IgA Nephropathy (TELIGAN) |
Primary Sjogren's Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05673993 | — | P3 | completed | A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome |
Myasthenia Gravis, Generalized (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05737160 | — | P3 | completed | Study of Telitacicept in Generalized Myasthenia Gravis |
ANCA-associated Vasculitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05965284 | TTCAZAREM | P4 | recruiting | Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) |
Antiphospholipid Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05644210 | — | N/A | unknown | Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE |
Lupus Erythematosus, Systemic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05899907 | — | P4 | unknown | Efficacy and Safety of Telitacicept in Early SLE |
Anti Phospholipid Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05078710 | — | P2 | terminated | Telitacicept in Primary APS Patients |
Telitacicept pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| TTCAAVREM | NCT05962840 | P4 | recruiting | ANCA Associated Vasculitis | 40 | — |
| TTCAZAREM | NCT05965284 | P4 | recruiting | ANCA-associated Vasculitis | 40 | — |
| UPSTREAM SjD | NCT07404865 | P3 | recruiting | Primary Sjogren's Disease | 250 | — |
| UPSTREAM MG | NCT06456580 | P3 | recruiting | Generalized Myasthenia Gravis | 180 | — |
| STERN | NCT06125405 | P3 | recruiting | Nephrotic Syndrome in Children | 20 | PMID 34193618 |
| OMG | NCT07249632 | P3 | recruiting | Myasthenia Gravis, Ocular | 120 | — |
| TELIGAN | NCT05799287 | P3 | active not recruiting | Primary IgA Nephropathy | 318 | — |
| REMESLE-2 | NCT06456567 | P3 | withdrawn | Systemic Lupus Erythematosus | 0 | — |
| REMESLE-1 | NCT05306574 | P3 | terminated | Systemic Lupus Erythematosus | 91 | — |
| TEST-T-PMN | NCT06614985 | P2 | not yet recruiting | Primary Membranous Nephropathy | 172 | — |
| RC18 | NCT04905212 | P2 | terminated | IgA Nephropathy | 15 | PMID 38299639 |
Terminated and withdrawn Telitacicept trials (4)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05078710terminatedTelitacicept in Primary APS Patients
- NCT06456567withdrawnA Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
- NCT05306574terminatedA Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
- NCT04905212terminatedA Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
All Telitacicept trials (46)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07495033 | Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease | P3 | not yet recruiting | 260 | RemeGen Co., Ltd. | Apr 2026 | |
| NCT07340463 | The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | P2 | recruiting | 50 | Nanjing University School of Medicine | Dec 2025 | |
| NCT07404865 | UPSTREAM SjD | Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease | P3 | recruiting | 250 | Vor Biopharma | Feb 2026 |
| NCT06456580 | UPSTREAM MG | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | P3 | recruiting | 180 | Vor Biopharma | Jul 2024 |
| NCT07522099 | Chinese Adults With Kidney Disease | P2 | recruiting | 30 | ADARx Pharmaceuticals, Inc. | May 2026 | |
| NCT07298928 | A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis | N/A | not yet recruiting | 30 | The Children's Hospital of Zhejiang University School of Medicine | Mar 2026 | |
| NCT06375005 | Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis | P2 | recruiting | 38 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jan 2025 | |
| NCT06677801 | Immune Cell Subsets in SLE Patients Treated with Telitacicept | P4 | active not recruiting | 50 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Oct 2024 | |
| NCT06125405 | STERN | Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome | P3 | recruiting | 20 | The Children's Hospital of Zhejiang University School of Medicine | Nov 2023 |
| NCT06614985 | TEST-T-PMN | The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy | P2 | not yet recruiting | 172 | Renmin Hospital of Wuhan University | Oct 2024 |
| NCT07052981 | Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis | P3 | not yet recruiting | 124 | Guixia Ding | Aug 2025 | |
| NCT06394063 | Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients | N/A | recruiting | 176 | RenJi Hospital | Jun 2024 | |
| NCT07111338 | Telitacicept for PGNMID: A Single-Arm Study | P2 | active not recruiting | 10 | Peking University First Hospital | Jul 2025 | |
| NCT06979271 | Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis | — | recruiting | 20 | Zhejiang Provincial People's Hospital | Jun 2025 | |
| NCT07355257 | TELITACICEPT-IM | TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) | P2/P3 | not yet recruiting | 30 | Zhongming Qiu | Feb 2026 |
| NCT07077486 | Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease | P4 | recruiting | 100 | Tongji Hospital | Aug 2025 | |
| NCT07249632 | OMG | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | P3 | recruiting | 120 | RemeGen Co., Ltd. | Jan 2026 |
| NCT06827587 | Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis | N/A | not yet recruiting | 60 | First Affiliated Hospital of Wenzhou Medical University | Feb 2025 | |
| NCT06723548 | Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis | P4 | not yet recruiting | 30 | First Affiliated Hospital of Wenzhou Medical University | Dec 2024 | |
| NCT06654596 | Efficacy and Safety of Telitacicept in IgAN | N/A | recruiting | 118 | Ruijin Hospital | Dec 2024 | |
| NCT05962840 | TTCAAVREM | Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) | P4 | recruiting | 40 | Chinese SLE Treatment And Research Group | Jun 2023 |
| NCT05965284 | TTCAZAREM | Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) | P4 | recruiting | 40 | Chinese SLE Treatment And Research Group | Mar 2023 |
| NCT06656962 | TEST-T-AAGN | The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) | P1/P2 | active not recruiting | 15 | Renmin Hospital of Wuhan University | Oct 2024 |
| NCT05596708 | Study of Telitacicept in Patients With Refractory IgA Nephropathy | P2/P3 | not yet recruiting | 40 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Mar 2023 | |
| NCT05799287 | TELIGAN | A Study of Telitacicept for IgA Nephropathy (TELIGAN) | P3 | active not recruiting | 318 | RemeGen Co., Ltd. | Apr 2023 |
| NCT06546540 | The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis | P4 | recruiting | 20 | Peking University Third Hospital | Jun 2024 | |
| NCT07008196 | Telitacicept for the Treatment of Refractory RA | P4 | not yet recruiting | 30 | Chinese SLE Treatment And Research Group | Jun 2025 | |
| NCT05680480 | A Study of Telitacicept in Lupus Nephritis | P2 | recruiting | 120 | RemeGen Co., Ltd. | Apr 2023 | |
| NCT06315530 | Effect of Telitacicept on Antibody Titers in Primary APS Patients | P2 | completed | 20 | Ruijin Hospital | Dec 2023 | |
| NCT05998759 | Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia | P2 | recruiting | 296 | Beijing Hospital | Dec 2023 | |
| NCT05644210 | Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE | — | unknown | 80 | Qilu Hospital of Shandong University | Oct 2022 | |
| NCT05687526 | A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus | P1 | completed | 16 | RemeGen Co., Ltd. | May 2023 | |
| NCT07098897 | To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy | P3 | active not recruiting | 150 | The Affiliated Hospital of Xuzhou Medical University | Aug 2024 | |
| NCT05899907 | Efficacy and Safety of Telitacicept in Early SLE | P4 | unknown | 180 | Peking Union Medical College Hospital | Sep 2022 | |
| NCT05339217 | Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus | P3 | unknown | 60 | Liu Tian | Feb 2023 | |
| NCT05078710 | Telitacicept in Primary APS Patients | P2 | terminated | 20 | Peking Union Medical College Hospital | Jul 2021 | |
| NCT05673993 | A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome | P3 | completed | 381 | RemeGen Co., Ltd. | Apr 2023 | |
| NCT06456567 | REMESLE-2 | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) | P3 | withdrawn | 0 | Vor Biopharma | Sep 2024 |
| NCT05306574 | REMESLE-1 | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) | P3 | terminated | 91 | Vor Biopharma | Jun 2022 |
| NCT06549959 | PK | A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects | P1 | recruiting | 248 | RemeGen Co., Ltd. | Aug 2024 |
| NCT05929248 | Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia | P2 | unknown | 64 | Guanmin Gao | Jul 2023 | |
| NCT05737160 | Study of Telitacicept in Generalized Myasthenia Gravis | P3 | completed | 114 | RemeGen Co., Ltd. | Mar 2023 | |
| NCT05666336 | Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients | P4 | unknown | 30 | Fen Li | Dec 2022 | |
| NCT05588830 | The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study | — | unknown | 60 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Oct 2022 | |
| NCT05247203 | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus | P1 | completed | 92 | RemeGen Co., Ltd. | May 2022 | |
| NCT04905212 | RC18 | A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy | P2 | terminated | 15 | RemeGen Co., Ltd. | Nov 2021 |
Telitacicept clinical trials: frequently asked questions
- How many Telitacicept clinical trials are there?
- 46 Telitacicept clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 17 are actively recruiting participants. 5 are marked completed.
- Are Telitacicept clinical trials recruiting in 2026?
- Yes — 17 Telitacicept trials are actively recruiting in 2026, with 46 U.S. sites across 18 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Telitacicept being studied for?
- Telitacicept is being studied for Systemic Lupus Erythematosus, Telitacicept, IgA Nephropathy (IgAN), Myasthenia Gravis, IgA Nephropathy and 42 more. The trials are grouped by indication on this page.
- What phase is Telitacicept in?
- Telitacicept clinical trials span 9 Phase 4, 13 Phase 3, 11 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Telitacicept clinical trials?
- The lead sponsor across the most Telitacicept trials is RemeGen Co., Ltd., with 24 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Telitaciceptas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: